The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
LAS VEGAS, Jan. 14, 2025 /PRNewswire/ -- URSROBOT, a leader in AI-driven robotics, is delighted to announce the resounding success of its presentation of...
LAS VEGAS, Jan. 14, 2025 /PRNewswire/ -- Building on the momentum of winning two CES Innovation Awards earlier this year, Baseus has achieved yet another...
LAS VEGAS, Jan. 14, 2025 /PRNewswire/ -- At CES 2025, held from January 7-10 in Las Vegas, ROMOSS captivated global audiences with its latest charging...
ADELAIDE, South Australia and PERTH, Western Australia, Jan. 14, 2025 /PRNewswire/ -- Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina announced a...